The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 224.00
Ask: 226.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.89%)
Open: 214.00
High: 234.50
Low: 214.00
Yest. Close: 221.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

Wed, 24th Feb 2021 10:25

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.



AIM - WINNERS



Mkango Resources Ltd, up 20% at 20.99 pence, 12-month range 2.2p-21p. The explorer for rare earth elements says it has begun its flotation pilot plant test work for the Songwe Hill rare earths project in Malawi. Mkango says flotation is a "key part" of the processing flowsheet for Songwe, with "significant" test work having been completed in South Africa, Canada and Australia in order to increase grade and recovery from those in its pre-feasibility study. "The start of pilot plant processing is a major milestone for the company and Mkango joins the ranks of the very few rare earths projects that have been advanced to this stage of development. We look forward to announcing results from the pilot plant when available," says Chief Executive William Dawes.



Best of the Best PLC, up 9.2% at 2,676.00 pence, 12-month range 310.9p-2,890p. The provider of online competitions to win cars and other prizes reports continued strong trading momentum. Says trading in the three months to the end of January has continued in line with the positive outlook set out in its interim results. "The Board is confident in the group's position and outlook for strong, sustained returns," says Chief Executive William Hindmarch.



Avacta, up 4.5% at 185.95p, 12-month range 12.62p-224.88p. The developer of Affimer biotherapeutics and reagents reports momentum in both the Diagnostics and Therapeutics divisions, adding that cash position at end of 2020 was GBP48 million, slightly higher than market forecasts. "We are very excited by the commercial potential of our scalable, rapid coronavirus test. The recently announced clinical data strongly reflects the excellent analytical performance demonstrated in the lab and suggests that it may be, to date, the most sensitive S1 spike protein lateral flow test. We are now confidently proceeding into full clinical validation to support a CE Mark, with a potential commercial launch for professional use around the end of the first quarter of this year," says Chief Executive Alastair Smith.



AIM - LOSERS



N4 Pharma PLC, up 7.6% at 8.55p, 12-month range 2p-16p. The pharmaceutical company reports widened loss for 2020 as research and development costs multiplied. Reports GBP1.6 million pretax loss for 2020, far wider than its GBP947,340 loss the year prior, as research and development costs surge to GBP900,410 in 2020 from only GBP216,948 the year before. N4 is still developing Nuvec, a delivery system for cancer treatments and vaccines, and so reported no revenue in either 2020 or 2019.



By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

11 Jun 21 12:27

Avacta Covid lateral flow test gets regulatory green light in EU

Avacta Covid lateral flow test gets regulatory green light in EU

11 Jun 21 11:40

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

7 Jun 21 11:31

Avacta gets MHRA registration for rapid Covid-19 test

(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.

7 Jun 21 10:11

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

1 Jun 21 20:24

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

1 Jun 21 11:16

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

28 May 21 11:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

28 May 21 07:29

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

10 May 21 11:13

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

22 Apr 21 12:17

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

20 Apr 21 15:18

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

20 Apr 21 12:17

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

20 Apr 21 11:35

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

15 Apr 21 14:56

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

6 Apr 21 13:53

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.